Antibody and Recombinant Protein CDMO Market, By Type; By Source Type; By Scale of Production; By Application; By End User, By Region, Global Trend Analysis, Competitive Landscape & Forecast, 2019-2030

Description

Global Antibody and Recombinant Protein CDMO Market to Cross USD 35 Billion by 2030

Global Antibody and Recombinant Protein CDMO Market is flourishing because of a rising demand for biopharma contract development and manufacturing services and increasingly complex processes involved in producing biologics.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Antibody and Recombinant Protein CDMO Market size at USD 16.70 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Antibody and Recombinant Protein CDMO Market size to expand at a CAGR of 11.2% reaching a value of USD 35.40 billion by 2030. Major growth factors for Global Antibody and Recombinant Protein CDMO Market include an increasing need for biologics and recombinant protein therapies. Over the forecast period, it is also expected that the growth of Global Antibody and Recombinant Protein CDMO Market will be spurred by the rising incidence of various chronic illnesses, including diabetes and cancer, scientific breakthroughs, and rising investments biopharmaceutical sector.

Opportunity - Major Acquisitions and Mergers

Many contract development and manufacturing organizations (CDMOs) are entering into mergers and acquisitions to expand their existing capacities. Small companies merge to leverage technology and platforms, while mid-size companies focus on diversifying pipelines through these strategic alliances. For instance, Curia, an American CDMO company, recently acquired Integrity Bio, a formulation and fill-finish company. In another example, Delpharm announced the acquisition of the Meppel pharmaceutical manufacturing facility in the Netherlands from Astellas to strengthen CDMO's position in the country. Such developments are anticipated to provide lucrative growth opportunities to global antibody and recombinant protein CDMO market during the period in analysis.

Impact of Escalating Geopolitical Tensions on Global Antibody and Recombinant Protein CDMO Market

Intensifying geopolitical tensions among countries spreading across the major regions could bring unprecedented challenges for Global Antibody and Recombinant Protein CDMO Market. A significant effect of geopolitical tensions on market operations is supply chain disruption, which makes it more difficult to get the necessary raw materials and reagents for the manufacturing of antibodies and recombinant proteins. Many exporting nations may apply tariffs or trade restrictions, which might make CDMOs' sourcing techniques more difficult. Product delivery on schedule may be impacted by delays in logistics and transportation caused by conflicts or increased security measures. Increased tensions may result in more stringent regulatory frameworks, which would affect CDMOs' capacity to conduct cross-border operations.

Therapeutics Segment Accounts for Major Market Share

The therapeutics segment holds the largest share of Global Antibody and Recombinant Protein CDMO Market. The growing prevalence of various chronic diseases owing to changing lifestyles and the rising geriatric populations is fueling the demand for recombinant protein therapeutics for treatment purposes. Recombinant protein therapeutics are widely used to treat various types of cancer. With the increasing prevalence of cancer worldwide, the demand for recombinant proteins is projected to rise only.

North America Holds Leadership Position in Global Market

North America dominates Global Antibody and Recombinant Protein CDMO Market. Expansion of the regional market is aided by the concentration of significant biotechnology and pharmaceutical firms as well as the strong healthcare systems in United States and Canada. However, over the forecast period, the Asia Pacific region is expected to register a significant growth rate. The Asia Pacific Antibody and Recombinant Protein CDMO Market is expected to be driven by the region's growing healthcare spending as well as an increase in research and development initiatives.

Competitive Landscape

Major industry players of Global Antibody and Recombinant Protein CDMO Market include Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Cerbios-Pharma SA, Gene Universal Inc., Eurogentec, MabPlex International, and Etinpro (Beijing) Co.

To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and Global Antibody and Recombinant Protein CDMO Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Antibody and Recombinant Protein CDMO Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Product Code: BWC24833

1. Research Framework

1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Executive Summary

3. Global Antibody and Recombinant Protein CDMO Market Insights

3.1. Industry Value Chain Analysis
3.2. DROC Analysis
- 3.2.1. Growth Drivers
  - 3.2.1.1. Increasing Demand for Biologics
  - 3.2.1.2. Complex Manufacturing Processes
  - 3.2.1.3. Continuous Advancements in Biotechnology
- 3.2.2. Restraints
  - 3.2.2.1. High Regulatory Hurdles
  - 3.2.2.2. Protecting Intellectual Property Rights
  - 3.2.2.3. Capacity Constraints
- 3.2.3. Opportunities
  - 3.2.3.1. Developing Countries with Growing Healthcare Infrastructure
  - 3.2.3.2. Rise of Personalized Medicine
  - 3.2.3.3. Rapid Development of Cell and Gene Therapies
- 3.2.4. Challenges
  - 3.2.4.1. Ensuring the Quality and Consistency of Biologic Products
  - 3.2.4.2. Increasing Competition and Cost Pressures
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry

4. Global Antibody and Recombinant Protein CDMO Market: Marketing Strategies

5. Global Antibody and Recombinant Protein CDMO Market: Pricing Analysis

6. Global Antibody and Recombinant Protein CDMO Market: Geographical Analysis

6.1. Global Antibody and Recombinant Protein CDMO Market, Geographical Analysis, 2023
6.2. Global Antibody and Recombinant Protein CDMO Market, Market Attractiveness Analysis, 2019-2030

7. Global Antibody and Recombinant Protein CDMO Market Overview

7.1. Market Size & Forecast, 2019-2030
- 7.1.1. By Value (USD Billion)
7.2. Market Share & Forecast
- 7.2.1. By Type
  - 7.2.1.1. Antibody CDMO
  - 7.2.1.2. Recombinant Protein CDMO
- 7.2.2. By Source Type
  - 7.2.2.1. Mammalian
  - 7.2.2.2. Microbial
  - 7.2.2.3. Others
- 7.2.3. By Scale of Production
  - 7.2.3.1. Clinical Manufacturing
  - 7.2.3.2. Commercial Manufacturing
- 7.2.4. By Application
  - 7.2.4.1. Therapeutics
  - 7.2.4.2. Research & Development
  - 7.2.4.3. Diagnostics
- 7.2.5. By End User
  - 7.2.5.1. Pharmaceutical & Biotechnology Companies
  - 7.2.5.2. Academic & Research Institutes
  - 7.2.5.3. Contract Research Organizations (CROs)
- 7.2.6. By Region
  - 7.2.6.1. North America
  - 7.2.6.2. Europe
  - 7.2.6.3. Asia Pacific (APAC)
  - 7.2.6.4. Latin America (LATAM)
  - 7.2.6.5. Middle East and Africa (MEA)

8. North America Antibody and Recombinant Protein CDMO Market

8.1. Market Size & Forecast, 2019-2030
- 8.1.1. By Value (USD Billion)
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Source Type
- 8.2.3. By Scale of Production
- 8.2.4. By Application
- 8.2.5. By End User
- 8.2.6. By Country
  - 8.2.6.1. United States
  - 8.2.6.1.1. By Type
  - 8.2.6.1.2. By Source Type
  - 8.2.6.1.3. By Scale of Production
  - 8.2.6.1.4. By Application
  - 8.2.6.1.5. By End User
  - 8.2.6.2. Canada
  - 8.2.6.2.1. By Type
  - 8.2.6.2.2. By Source Type
  - 8.2.6.2.3. By Scale of Production
  - 8.2.6.2.4. By Application
  - 8.2.6.2.5. By End User

9. Europe Antibody and Recombinant Protein CDMO Market

9.1. Market Size & Forecast, 2019-2030
- 9.1.1. By Value (USD Billion)
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Source Type
- 9.2.3. By Scale of Production
- 9.2.4. By Application
- 9.2.5. By End User
- 9.2.6. By Country
  - 9.2.6.1. Germany
  - 9.2.6.1.1. By Type
  - 9.2.6.1.2. By Source Type
  - 9.2.6.1.3. By Scale of Production
  - 9.2.6.1.4. By Application
  - 9.2.6.1.5. By End User
  - 9.2.6.2. United Kingdom
  - 9.2.6.2.1. By Type
  - 9.2.6.2.2. By Source Type
  - 9.2.6.2.3. By Scale of Production
  - 9.2.6.2.4. By Application
  - 9.2.6.2.5. By End User
  - 9.2.6.3. Italy
  - 9.2.6.3.1. By Type
  - 9.2.6.3.2. By Source Type
  - 9.2.6.3.3. By Scale of Production
  - 9.2.6.3.4. By Application
  - 9.2.6.3.5. By End User
  - 9.2.6.4. France
  - 9.2.6.4.1. By Type
  - 9.2.6.4.2. By Source Type
  - 9.2.6.4.3. By Scale of Production
  - 9.2.6.4.4. By Application
  - 9.2.6.4.5. By End User
  - 9.2.6.5. Spain
  - 9.2.6.5.1. By Type
  - 9.2.6.5.2. By Source Type
  - 9.2.6.5.3. By Scale of Production
  - 9.2.6.5.4. By Application
  - 9.2.6.5.5. By End User
  - 9.2.6.6. Belgium
  - 9.2.6.6.1. By Type
  - 9.2.6.6.2. By Source Type
  - 9.2.6.6.3. By Scale of Production
  - 9.2.6.6.4. By Application
  - 9.2.6.6.5. By End User
  - 9.2.6.7. Russia
  - 9.2.6.7.1. By Type
  - 9.2.6.7.2. By Source Type
  - 9.2.6.7.3. By Scale of Production
  - 9.2.6.7.4. By Application
  - 9.2.6.7.5. By End User
  - 9.2.6.8. The Netherlands
  - 9.2.6.8.1. By Type
  - 9.2.6.8.2. By Source Type
  - 9.2.6.8.3. By Scale of Production
  - 9.2.6.8.4. By Application
  - 9.2.6.8.5. By End User
  - 9.2.6.9. Rest of Europe
  - 9.2.6.9.1. By Type
  - 9.2.6.9.2. By Source Type
  - 9.2.6.9.3. By Scale of Production
  - 9.2.6.9.4. By Application
  - 9.2.6.9.5. By End User

10. Asia Pacific Antibody and Recombinant Protein CDMO Market

10.1. Market Size & Forecast, 2019-2030
- 10.1.1. By Value (USD Billion)
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Source Type
- 10.2.3. By Scale of Production
- 10.2.4. By Application
- 10.2.5. By End User
- 10.2.6. By Country
  - 10.2.6.1. China
  - 10.2.6.1.1. By Type
  - 10.2.6.1.2. By Source Type
  - 10.2.6.1.3. By Scale of Production
  - 10.2.6.1.4. By Application
  - 10.2.6.1.5. By End User
  - 10.2.6.2. India
  - 10.2.6.2.1. By Type
  - 10.2.6.2.2. By Source Type
  - 10.2.6.2.3. By Scale of Production
  - 10.2.6.2.4. By Application
  - 10.2.6.2.5. By End User
  - 10.2.6.3. Japan
  - 10.2.6.3.1. By Type
  - 10.2.6.3.2. By Source Type
  - 10.2.6.3.3. By Scale of Production
  - 10.2.6.3.4. By Application
  - 10.2.6.3.5. By End User
  - 10.2.6.4. South Korea
  - 10.2.6.4.1. By Type
  - 10.2.6.4.2. By Source Type
  - 10.2.6.4.3. By Scale of Production
  - 10.2.6.4.4. By Application
  - 10.2.6.4.5. By End User
  - 10.2.6.5. Australia & New Zealand
  - 10.2.6.5.1. By Type
  - 10.2.6.5.2. By Source Type
  - 10.2.6.5.3. By Scale of Production
  - 10.2.6.5.4. By Application
  - 10.2.6.5.5. By End User
  - 10.2.6.6. Indonesia
  - 10.2.6.6.1. By Type
  - 10.2.6.6.2. By Source Type
  - 10.2.6.6.3. By Scale of Production
  - 10.2.6.6.4. By Application
  - 10.2.6.6.5. By End User
  - 10.2.6.7. Malaysia
  - 10.2.6.7.1. By Type
  - 10.2.6.7.2. By Source Type
  - 10.2.6.7.3. By Scale of Production
  - 10.2.6.7.4. By Application
  - 10.2.6.7.5. By End User
  - 10.2.6.8. Singapore
  - 10.2.6.8.1. By Type
  - 10.2.6.8.2. By Source Type
  - 10.2.6.8.3. By Scale of Production
  - 10.2.6.8.4. By Application
  - 10.2.6.8.5. By End User
  - 10.2.6.9. Vietnam
  - 10.2.6.9.1. By Type
  - 10.2.6.9.2. By Source Type
  - 10.2.6.9.3. By Scale of Production
  - 10.2.6.9.4. By Application
  - 10.2.6.9.5. By End User
  - 10.2.6.10. Rest of APAC
  - 10.2.6.10.1. By Type
  - 10.2.6.10.2. By Source Type
  - 10.2.6.10.3. By Scale of Production
  - 10.2.6.10.4. By Application
  - 10.2.6.10.5. By End User

11. Latin America Antibody and Recombinant Protein CDMO Market

11.1. Market Size & Forecast, 2019-2030
- 11.1.1. By Value (USD Billion)
11.2. Market Share & Forecast
- 11.2.1. By Type
- 11.2.2. By Source Type
- 11.2.3. By Scale of Production
- 11.2.4. By Application
- 11.2.5. By End User
- 11.2.6. By Country
  - 11.2.6.1. Brazil
  - 11.2.6.1.1. By Type
  - 11.2.6.1.2. By Source Type
  - 11.2.6.1.3. By Scale of Production
  - 11.2.6.1.4. By Application
  - 11.2.6.1.5. By End User
  - 11.2.6.2. Mexico
  - 11.2.6.2.1. By Type
  - 11.2.6.2.2. By Source Type
  - 11.2.6.2.3. By Scale of Production
  - 11.2.6.2.4. By Application
  - 11.2.6.2.5. By End User
  - 11.2.6.3. Argentina
  - 11.2.6.3.1. By Type
  - 11.2.6.3.2. By Source Type
  - 11.2.6.3.3. By Scale of Production
  - 11.2.6.3.4. By Application
  - 11.2.6.3.5. By End User
  - 11.2.6.4. Peru
  - 11.2.6.4.1. By Type
  - 11.2.6.4.2. By Source Type
  - 11.2.6.4.3. By Scale of Production
  - 11.2.6.4.4. By Application
  - 11.2.6.4.5. By End User
  - 11.2.6.5. Rest of LATAM
  - 11.2.6.5.1. By Type
  - 11.2.6.5.2. By Source Type
  - 11.2.6.5.3. By Scale of Production
  - 11.2.6.5.4. By Application
  - 11.2.6.5.5. By End User

12. Middle East & Africa Antibody and Recombinant Protein CDMO Market

12.1. Market Size & Forecast, 2019-2030
- 12.1.1. By Value (USD Billion)
12.2. Market Share & Forecast
- 12.2.1. By Type
- 12.2.2. By Source Type
- 12.2.3. By Scale of Production
- 12.2.4. By Application
- 12.2.5. By End User
- 12.2.6. By Country
  - 12.2.6.1. Saudi Arabia
  - 12.2.6.1.1. By Type
  - 12.2.6.1.2. By Source Type
  - 12.2.6.1.3. By Scale of Production
  - 12.2.6.1.4. By Application
  - 12.2.6.1.5. By End User
  - 12.2.6.2. UAE
  - 12.2.6.2.1. By Type
  - 12.2.6.2.2. By Source Type
  - 12.2.6.2.3. By Scale of Production
  - 12.2.6.2.4. By Application
  - 12.2.6.2.5. By End User
  - 12.2.6.3. Qatar
  - 12.2.6.3.1. By Type
  - 12.2.6.3.2. By Source Type
  - 12.2.6.3.3. By Scale of Production
  - 12.2.6.3.4. By Application
  - 12.2.6.3.5. By End User
  - 12.2.6.4. Kuwait
  - 12.2.6.4.1. By Type
  - 12.2.6.4.2. By Source Type
  - 12.2.6.4.3. By Scale of Production
  - 12.2.6.4.4. By Application
  - 12.2.6.4.5. By End User
  - 12.2.6.5. South Africa
  - 12.2.6.5.1. By Type
  - 12.2.6.5.2. By Source Type
  - 12.2.6.5.3. By Scale of Production
  - 12.2.6.5.4. By Application
  - 12.2.6.5.5. By End User
  - 12.2.6.6. Nigeria
  - 12.2.6.6.1. By Type
  - 12.2.6.6.2. By Source Type
  - 12.2.6.6.3. By Scale of Production
  - 12.2.6.6.4. By Application
  - 12.2.6.6.5. By End User
  - 12.2.6.7. Algeria
  - 12.2.6.7.1. By Type
  - 12.2.6.7.2. By Source Type
  - 12.2.6.7.3. By Scale of Production
  - 12.2.6.7.4. By Application
  - 12.2.6.7.5. By End User
  - 12.2.6.8. Rest of MEA
  - 12.2.6.8.1. By Type
  - 12.2.6.8.2. By Source Type
  - 12.2.6.8.3. By Scale of Production
  - 12.2.6.8.4. By Application
  - 12.2.6.8.5. By End User

13. Competitive Landscape

13.1. List of Key Players and Their Offerings
13.2. Global Antibody and Recombinant Protein CDMO Company Market Share Analysis, 2023
13.3. Competitive Benchmarking, By Operating Parameters
13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

14. Impact of Escalating Geopolitical Tensions on Global Antibody and Recombinant Protein CDMO Market

15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

15.1. Batavia Biosciences
15.2. Grifols
15.3. Cerbios-Pharma SA
15.4. HALIX
15.5. Biovian Oy
15.6. Catalent
15.7. Goodwin Biotechnology
15.8. Cerbios-Pharma SA
15.9. Gene Universal Inc.
15.10. Eurogentec
15.11. MabPlex International
15.12. Etinpro (Beijing) Co
15.13. Other Prominent Players

16. Key Strategic Recommendations

17. Research Methodology

17.1. Qualitative Research
- 17.1.1. Primary & Secondary Research
17.2. Quantitative Research
17.3. Market Breakdown & Data Triangulation
- 17.3.1. Secondary Research
- 17.3.2. Primary Research
17.4. Breakdown of Primary Research Respondents, By Region
17.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable